

ASTRAZENECA PLC
Form 6-K
August 01, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of August 2013

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Line Extensions		Development Pipeline as at 30 June 2013							
Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing US	Estimated Filing EU	Japan	China	
Axanum***	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer in high risk CV patients	III		Withdrawn	Launched			
Brilinta/ Brilique EUCLID	ADP receptor antagonist	outcomes study in patients with PAD	III	4Q 2012	2016	2016	2016	2017	
Brilinta / Brilique PEGASUS-TIMI 54	ADP receptor antagonist	outcomes study in patients with prior MI	III	4Q 2010	2015	2015	2015	2017	
Bydureon EXSCEL#	GLP-1 receptor agonist	outcomes study	III	2Q 2010	2018	2018	2018		
Bydureon Dual Chamber Pen#	GLP-1 receptor agonist	diabetes	III		3Q 2013	4Q 2013			
Forxiga (dapagliflozin)/ metformin FDC#	SGLT2 inhibitor + metformin FDC	diabetes	III	3Q 2007	4Q 2013	Filed			
Forxiga (dapagliflozin)#	SGLT2 inhibitor	diabetes - add on to DPP-4	III	1Q 2010		Filed			
Forxiga (dapagliflozin)#	SGLT2 inhibitor	diabetes - add on to insulin and add-on to metformin	III	2Q 2008		Filed			
Forxiga (dapagliflozin)#	SGLT2 inhibitor	long-term data diabetes - in patients with high CV risk - Study 18 and 19	III	1Q 2010		1H 2014			
		long-term data							

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Forxiga (dapagliflozin)#	SGLT2 inhibitor	diabetes - triple therapy (dapa+met+ SU)	III	1Q 2011		4Q 2013		
Forxiga (dapagliflozin) DECLARE#	SGLT2 inhibitor	outcomes study	III	2Q 2013	2020	2020		
Kombiglyze XR/ Komboglyze FDC#*	DPP-4 inhibitor + metformin FDC	diabetes	III		Launched	Launched		1H 2014
SaxaDapa FDC#	DPP-4 inhibitor / SGLT2 inhibitor	diabetes	III	2Q 2012	2015	2015		
Onglyza SAVOR-TIMI 53#	DPP-4 inhibitor	outcomes study	III	2Q 2010	4Q 2013	4Q 2013		2H 2014

Compound	Mechanism	Area Under Investigation	Phase	D a t e Commenced Phase	Estimated US	Filing EU	Japan	China
Gastrointestinal								
Entocort	glucocorticoid steroid	Crohn's disease / ulcerative colitis	III		Launched	Launched	2015	N/A
Nexium	proton pump inhibitor	peptic ulcer bleeding	III		Filed**	Launched	N/A	Launched
Neuroscience								
Diprivan#	sedative and anaesthetic	conscious sedation	III			Launched	2H 2014	Launched
Oncology								
Faslodex	oestrogen receptor antagonist	1st line advanced breast cancer	III	4Q 2012	2016	2016	2016	2016
Iressa	tyrosine kinase inhibitor	treatment beyond progression	III	1Q 2012		2015	2015	2015
Respiratory, Inflammation & Autoimmunity								
Symbicort	inhaled steroid/ long-acting agonist	Breath Actuated 2/ Inhaler asthma COPD	III	4Q 2011	1H 2014			

#Partnered product

*Kombiglyze XR US; Komboglyze FDC EU

Edgar Filing: ASTRAZENECA PLC - Form 6-K

**2nd CRL received from FDA in 2011. AZ response submitted to FDA in December 2012

***Commercial support now withdrawn, no Japan launch expected

NCEs

Phase III/Registration

Compound	Mechanism	Area Under Investigation	Phase D a t e Commenced Phase	Estimated Filing US	EU	Japan	China
Cardiovascular							
Brilinta/ Brilique	ADP receptor antagonist	arterial thrombosis	III	Launched	Launched	Filed	Launched
Epanova#	omega-3 free fatty acids	hypertri-glyceridaemia	III	Filed			
Forxiga (dapagliflozin)#	SGLT2 inhibitor	diabetes	III	Filed*	Launched	Filed	Filed
metreleptin#	leptin analogue	lipodystrophy	III	Filed	1H 2014	N/A	
Infection							
CAZ AVI# (CAZ104)	beta lactamase inhibitor/ cepha-losporin	intra abdominal infections (cIAI) & urinary tract infections (cUTI); hospital acquired pneumonia (HAP) & ventilator associated pneumonia (VAP) ***	III	1Q 2012	N/A	2H 2014	2015 2016
Q-LAIV Flu Vaccination**	live, attenuated, intranasal influenza virus vaccine quadrivalent extended spectrum	seasonal influenza	III	Approved	Filed		
Zinforo (ceftaroline) #	cepha-losporin with affinity to penicillin- binding proteins	pneumonia / skin infections	III	N/A	Launched		1H 2014
Neuroscience							
naloxegol (NKTR-118)#	oral peripherally-acting mu-opioid receptor antagonist	opioid-induced constipation	III	2Q 2011	3Q 2013	3Q 2013	
Oncology							
Caprelsa	VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III	Launched	Launched	2015	Filed
moxetumomab pasudotox#	anti-CD22 recombinant immunotoxin	hairy cell leukaemia	III	2Q 2013	2017	2017	

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing US	EU	Japan	China
Respiratory, Inflammation & Autoimmunity								
brodalumab#	anti-IL-17R MAb	psoriasis	III	3Q 2012	2015	2015		
PT003 GFF	LABA/LAMA	COPD	III	2Q 2013	2015	2016		
lesinurad	selective uric acid reabsorption inhibitor (SURI)	chronic treatment of patients with gout	III	4Q 2011	2H 2014	2H 2014	2017	2017

#Partnered product

*CRL received in January 2012, re-submission 3Q 2013

**sBLA in US, MAA in EU

***HAP/VAP is a follow up filing, EU filing expected in 2017

NCEs

Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing US	EU	Japan	China
Cardiovascular								
AZD1722#	NHE3 inhibitor	end stage renal disease / chronic kidney disorder	II	1Q 2013				
MEDI6012 (ACP-501)	LCAT	ACS	I	1Q 2012				
Infection								
AZD5847	oxazolidinone anti-bacterial inhibitor	tuberculosis	II	4Q 2012				
CXL#	beta lactamase inhibitor/ cephalosporin	MRSA	II	4Q 2010				
ATM AVI	BL/BLI	targeted serious bacterial infections hospital-acquired	I	4Q 2012				
MEDI4893	staph alpha toxin YTE MAb	pneumonia / serious S. aureus infection	I	1Q 2013				
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I	2Q 2006				
PRVV (MEDI-559)	live attenuated paediatric RSV	RSV prophylaxis	I	4Q 2008				

Edgar Filing: ASTRAZENECA PLC - Form 6-K

	vaccine				
Neuroscience					
AZD3241	myeloper-oxidase (MPO) inhibitor	Parkinson's disease	II	2Q 2012	
AZD5213	histamine-3 receptor antagonist	neuropathic pain*	II		
AZD6765	NMDA receptor antagonist	major depressive disorder	II	3Q 2007	
AZD3293#	beta secretase	Alzheimer's disease	I	4Q 2012	

#Partnered product

*Terminated in Alzheimer's Disease - neuropathic pain study due to start 3Q 2013

NCEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	D a t e Commenced Phase	eEstimated Filing US	EU	Japan	China
Oncology								
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	II	4Q 2011				
MEDI-551#	anti-CD19 MAb	haematological malignancies	II	1Q 2012				
MEDI-573#	anti-IGF MAb	MBC	II	4Q 2011				
olaparib	PARP inhibitor	gBRCAm ovarian cancer, gBRCAm breast cancer, gastric cancer	II	1Q 2012				
selumetinib# (AZD6244) (ARRY-142886)	MEK inhibitor	solid tumours	II	4Q 2006				
tremelimumab	anti-CTLA4 MAb	solid tumours	II	3Q 2004				
AZD1208	PIM kinase inhibitor	haematological malignancies	I	1Q 2012				
AZD2014	TOR kinase inhibitor	solid tumours	I	1Q 2010				
AZD5363#	AKT inhibitor	solid tumours	I	4Q 2010				
AZD8186	PI3 kinase inhibitor	solid tumours	I	2Q 2013				
AZD9150#	beta inhibitor	solid tumours	I	1Q 2012				

Edgar Filing: ASTRAZENECA PLC - Form 6-K

AZD9291	STAT3 inhibitor epidermal growth factor inhibitor	haematological malignancies solid tumours	I	1Q 2013
MEDI0639#	anti-DLL-4 MAb	solid tumours	I	2Q 2012
MEDI3617#	anti-ANG-2 MAb	solid tumours	I	4Q 2010
MEDI4736#	anti-PD-L1 MAb	solid tumours	I	3Q 2012
MEDI-565#	anti-CEA BiTE	solid tumours	I	1Q 2011
MEDI6469#	murine anti-OX40 MAb	solid tumours	I	1Q 2006
volitinib#	MET inhibitor	solid tumours	I	1Q 2012

#Partnered product

NCEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced	Estimated Filing Phase	US	EU	Japan	China
Respiratory, Inflammation & Autoimmunity									
AZD2115#	MABA	COPD	II	2Q 2012					
AZD5069	CXCR2	asthma	II	4Q 2010					
AZD5423#	inhaled SGRM	COPD	II	4Q 2010					
benralizumab#	anti-IL-5R MAb	asthma / COPD	II	4Q 2008					
mavrilimumab#	anti-GM-CSFR MAb	rheumatoid arthritis	II	1Q 2010					
MEDI2070#	anti-IL-23 MAb	Crohn's disease	II	1Q 2013					
MEDI-546#	anti-IFN-alphaR MAb	SLE	II	1Q 2012					
MEDI7183#	anti-a4b7 MAb	Crohn's disease / ulcerative colitis	II	4Q 2012					
MEDI8968#	anti-IL-1R MAb	COPD, HS	II	4Q 2011					
sifalimumab#	anti-IFN-alpha MAb	SLE	II	3Q 2008					
tralokinumab	anti-IL-13 MAb	asthma / IPF / UC	II	1Q 2008					

Edgar Filing: ASTRAZENECA PLC - Form 6-K

AZD8848#	inhaled TLR7	asthma	I	2Q 2012
AZD7594#	inhaled SGRM	COPD	I	4Q 2012
AZD7624	ip38i	COPD	I	1Q 2013
MEDI-551#	anti-CD19 MAb	multiple sclerosis	I	3Q 2012
MEDI5872#	anti-B7RP1 MAb	SLE	I	4Q 2008
MEDI9929#	anti-TSLP MAb	asthma	I	4Q 2008
RDEA3170	selective uric acid reabsorption inhibitor (SURI)	chronic treatment of patients with gout	I	3Q 2011

#Partnered product

Development Pipeline - Discontinued Projects between 1 January 2013 and 30 June 2013

Infection

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	MEDI-557	safety / efficacy	RSV prevention in high risk adults (COPD/CHF/other)

Neuroscience

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD1446	safety / efficacy	Alzheimer's disease
NCE	AZD3480	safety / efficacy	Alzheimer's disease
NCE	MEDI5117	safety / efficacy	rheumatoid arthritis

Oncology

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD8330#(ARRY 424704)	safety / efficacy	solid tumours
NCE	fostamatinib	safety / efficacy	haematological malignancies
NCE	MEDI-575	safety / efficacy	NSCLC

Respiratory, Inflammation & Autoimmunity

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	fostamatinib	safety / efficacy	rheumatoid arthritis
NCE	MEDI7814	economic	COPD
NCE	MEDI4212	safety / efficacy	asthma

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Submission dates shown for assets in Phase III and beyond.

- ENDS -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 August 2013

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary